Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Details) - Schedule of segment reporting information, by segment

Segment reporting (Details) - Schedule of segment reporting information, by segment (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Revenues:
Clinical laboratory services	$ 14,725us-gaap_SalesRevenueServicesNet	$ 13,848us-gaap_SalesRevenueServicesNet	$ 30,547us-gaap_SalesRevenueServicesNet	$ 28,707us-gaap_SalesRevenueServicesNet
Product revenues	7,723us-gaap_SalesRevenueGoodsNet	8,054us-gaap_SalesRevenueGoodsNet	15,725us-gaap_SalesRevenueGoodsNet	15,717us-gaap_SalesRevenueGoodsNet
Royalty and license fee income	644enz_RoyaltyAndLicenseFeeIncome	1,026enz_RoyaltyAndLicenseFeeIncome	1,644enz_RoyaltyAndLicenseFeeIncome	2,637enz_RoyaltyAndLicenseFeeIncome
Total revenues	23,092us-gaap_SalesRevenueNet	22,928us-gaap_SalesRevenueNet	47,916us-gaap_SalesRevenueNet	47,061us-gaap_SalesRevenueNet
Operating expenses:
Cost of clinical laboratory services	9,246us-gaap_CostOfServices	9,292us-gaap_CostOfServices	19,376us-gaap_CostOfServices	19,001us-gaap_CostOfServices
Cost of product revenues	3,818us-gaap_CostOfGoodsSold	3,865us-gaap_CostOfGoodsSold	7,513us-gaap_CostOfGoodsSold	7,712us-gaap_CostOfGoodsSold
Research and development	834us-gaap_ResearchAndDevelopmentExpense	832us-gaap_ResearchAndDevelopmentExpense	1,625us-gaap_ResearchAndDevelopmentExpense	1,649us-gaap_ResearchAndDevelopmentExpense
Selling, general and administrative	9,670	10,084	19,955	20,612
Provision for uncollectible accounts receivable	601us-gaap_ProvisionForDoubtfulAccounts	912us-gaap_ProvisionForDoubtfulAccounts	1,142us-gaap_ProvisionForDoubtfulAccounts	1,784us-gaap_ProvisionForDoubtfulAccounts
Legal fee expense	2,804us-gaap_LegalFees	1,496us-gaap_LegalFees	5,270us-gaap_LegalFees	2,877us-gaap_LegalFees
Operating income (loss)	(3,881)us-gaap_OperatingIncomeLoss	(3,553)us-gaap_OperatingIncomeLoss	(6,965)us-gaap_OperatingIncomeLoss	(6,574)us-gaap_OperatingIncomeLoss
Other income (expense)
Other	(17)us-gaap_OtherNonoperatingIncomeExpense	15us-gaap_OtherNonoperatingIncomeExpense	2us-gaap_OtherNonoperatingIncomeExpense	76us-gaap_OtherNonoperatingIncomeExpense
Foreign exchange gain (loss)	(259)	20	(731)	317
Share-based compensation included in above:
Share-based compensation	105	109	203	212
Cost of Clinical Laboratory Services [Member] \| Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	2	2	3	4
Cost of Clinical Laboratory Services [Member] \| Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	2	2	3	4
Cost of Clinical Laboratory Services [Member]
Share-based compensation included in above:
Share-based compensation	2	2	3	4
Research and Development Expense [Member] \| Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	1		2	1
Research and Development Expense [Member] \| Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	1		2	1
Research and Development Expense [Member]
Share-based compensation included in above:
Share-based compensation	1		2	1
Selling, General and Administrative Expenses [Member] \| Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	12	9	21	19
Selling, General and Administrative Expenses [Member] \| Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	3	5	3	9
Selling, General and Administrative Expenses [Member] \| Other Segments [Member]
Share-based compensation included in above:
Share-based compensation	87	93	174	179
Selling, General and Administrative Expenses [Member] \| Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	102	107	198	207
Selling, General and Administrative Expenses [Member]
Share-based compensation included in above:
Share-based compensation	102	107	198	207
Total [Member] \| Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	14	11	24	23
Total [Member] \| Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	4	5	5	10
Total [Member] \| Other Segments [Member]
Share-based compensation included in above:
Share-based compensation	87	93	174	179
Total [Member] \| Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	105	109	203	212
Clinical Labs [Member]
Revenues:
Clinical laboratory services	14,725	13,848	30,547	28,707
Total revenues	14,725	13,848	30,547	28,707
Operating expenses:
Cost of clinical laboratory services	9,246	9,292	19,376	19,001
Research and development		3		14
Selling, general and administrative	5,089	4,981	10,157	10,031
Provision for uncollectible accounts receivable	658	920	1,189	1,764
Legal fee expense	41	142	131	290
Total operating expenses	15,034	15,338	30,853	31,100
Operating income (loss)	(309)	(1,490)	(306)	(2,393)
Other income (expense)
Interest	(12)	(11)	(39)	(22)
Other	4	9	6	27
Income (loss) before income taxes	(317)	(1,492)	(339)	(2,388)
Depreciation and amortization included above	357	355	714	710
Share-based compensation included in above:
Capital expenditures	338	103	589	362
Life Sciences [Member]
Revenues:
Product revenues	7,723	8,054	15,725	15,717
Royalty and license fee income	644	1,026	1,644	2,637
Total revenues	8,367	9,080	17,369	18,354
Operating expenses:
Cost of product revenues	3,818	3,865	7,513	7,712
Research and development	635	543	1,183	1,069
Selling, general and administrative	2,704	3,318	5,853	6,813
Provision for uncollectible accounts receivable	(57)	(8)	(47)	20
Legal fee expense	(53)	15	(51)	37
Total operating expenses	7,047	7,733	14,451	15,651
Operating income (loss)	1,320	1,347	2,918	2,703
Other income (expense)
Interest	5	3	7	8
Other	(29)	(6)	(35)	21
Foreign exchange gain (loss)	(259)	20	(731)	317
Income (loss) before income taxes	1,037	1,364	2,159	3,049
Depreciation and amortization included above	555	621	1,113	1,262
Share-based compensation included in above:
Capital expenditures	51	7	64	82
Therapeutics [Member]
Operating expenses:
Research and development	199	286	442	566
Total operating expenses	199	286	442	566
Operating income (loss)	(199)	(286)	(442)	(566)
Other income (expense)
Income (loss) before income taxes	(199)	(286)	(442)	(566)
Depreciation and amortization included above	1	2	2	6
Other Segments [Member]
Operating expenses:
Selling, general and administrative	1,877	1,785	3,945	3,768
Legal fee expense	2,816	1,339	5,190	2,550
Total operating expenses	4,693	3,124	9,135	6,318
Operating income (loss)	(4,693)	(3,124)	(9,135)	(6,318)
Other income (expense)
Interest	(42)	(44)	(86)	(100)
Other	8	12	31	28
Income (loss) before income taxes	(4,727)	(3,156)	(9,190)	(6,390)
Depreciation and amortization included above	22	24	44	49
Consolidated [Member]
Revenues:
Clinical laboratory services	14,725	13,848	30,547	28,707
Product revenues	7,723	8,054	15,725	15,717
Royalty and license fee income	644	1,026	1,644	2,637
Total revenues	23,092	22,928	47,916	47,061
Operating expenses:
Cost of clinical laboratory services	9,246	9,292	19,376	19,001
Cost of product revenues	3,818	3,865	7,513	7,712
Research and development	834	832	1,625	1,649
Selling, general and administrative	9,670	10,084	19,955	20,612
Provision for uncollectible accounts receivable	601	912	1,142	1,784
Legal fee expense	2,804	1,496	5,270	2,877
Total operating expenses	26,973	26,481	54,881	53,635
Operating income (loss)	(3,881)	(3,553)	(6,965)	(6,574)
Other income (expense)
Interest	(49)	(52)	(118)	(114)
Other	(17)	15	2	76
Foreign exchange gain (loss)	(259)	20	(731)	317
Income (loss) before income taxes	(4,206)	(3,570)	(7,812)	(6,295)
Depreciation and amortization included above	935	1,002	1,873	2,027
Share-based compensation included in above:
Capital expenditures	$ 389	$ 110	$ 653	$ 444